Also known as: Zydus Lifesciences
Zydus Lifesciences is a fully integrated global healthcare provider and leading Indian pharmaceutical company. It develops formulations, active pharmaceutical ingredients, animal healthcare products, and wellness products across a broad healthcare value chain.
Recent biosimilar and biologic developments included Health Canada approval of denosumab biosimilars, FDA review actions, and new licensing and commercialisation agreements. Other updates covered court, trial and reimbursement agenda decisions.
Generic semaglutide launched in India as Novo Nordisk’s patent expired, with prices starting below Rs 1,300 a month. Doctors and companies said device quality, cold chains and patient support will also shape sales.
Multiple Indian pharmaceutical companies including Zydus, Glenmark, Dr. Reddy's, and Alkem have launched semaglutide versions following patent expiry, dramatically reducing prices and expanding access. Companies are competing on both price and innovative delivery systems, with monthly therapy costs now ranging from Rs 1,300 to Rs 4,200. This development could significantly impact diabetes and obesity treatment in India, where over 100 million people live with diabetes.
Seven Indian pharmaceutical companies have launched generic semaglutide drugs at prices 70-80% lower than Novo Nordisk's Ozempic following patent expiration. Novo Nordisk has cut prices by 37% to maintain market share as competition intensifies in India's growing weight-loss drug market.
China's NMPA approved Desidustat Tablets on March 13, 2026, for treating anemia in non-dialysis CKD patients. Clinical trials showed the oral HIF-PHI was non-inferior to erythropoietin in maintaining hemoglobin levels with improved quality of life.
Zydus Lifesciences launched ANYRA, India's first indigenously developed aflibercept biosimilar, on February 19, 2026, following an agreement with Regeneron Pharmaceuticals and Bayer for multiple ophthalmic indications.
Zydus Lifesciences received USFDA final approval for 32 mg bosentan tablets for pediatric PAH and Ammonium Lactate Cream, 12%, while launching an affordable respiratory device in India.
Zydus Lifesciences launched ANYRA, India's first indigenous Aflibercept biosimilar for retinal conditions, and secured approval for a March 2026 day-one launch of generic semaglutide for diabetes and obesity treatment.
Zydus Lifesciences plans to launch Semaglutide injection in India after patent expiry and introduced ANYRA, India's first indigenous Aflibercept biosimilar. The USFDA cleared the company's Ahmedabad injectable facility with zero observations.
The patent for semaglutide, the active ingredient in Ozempic, expires March 20, 2026. Indian pharmaceutical companies are preparing to launch generic versions, with prices expected to be 30-50% lower than branded products.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06815835 |
Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months |
NOT_YET_RECRUITING | PHASE3 |
| NCT06757283 |
ZyVac-TCV Bangladesh Study |
NOT_YET_RECRUITING | PHASE3 |
| NCT06398808 |
A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates |
COMPLETED | PHASE2 |
| NCT05981040 |
Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis |
COMPLETED | PHASE2 |
| NCT05911828 |
A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers |
RECRUITING | PHASE1 |
| NCT05872269 |
A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities |
RECRUITING | PHASE4 |
| NCT05515367 |
A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study) |
RECRUITING | PHASE4 |
| NCT05283837 |
A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) |
COMPLETED | PHASE3 |
| NCT05206201 |
A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects |
COMPLETED | PHASE1 |
| NCT05186051 |
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS) |
COMPLETED | PHASE2 |
